Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Marinus Stock Surges on Successful Phase II Epilepsy Study

by Zacks Equity Research

Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.

    Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA

    by Zacks Equity Research

    Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.

      Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

      by Zacks Equity Research

      Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

        Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints

        by Zacks Equity Research

        Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi's (SNY) Dupixent (dupilumab) met two primary endpoints in phase III study.

          AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb

          by Zacks Equity Research

          AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.

            Celgene (CELG) Fusion Program Studies Put on Hold by FDA

            by Zacks Equity Research

            Celgene Corporation (CELG) announced that the FDA put a hold on several trials in the FUSION program evaluating Imfinzi, an anti-PD-L1 antibody, in combination with immunomodulatory and chemotherapy agents in blood cancers.

              Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold

              by Zacks Equity Research

              Bristol-Myers Squibb Company (BMY) announced that the FDA put a partial clinical hold on three clinical trials, investigating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma.

                Why Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report?

                by Zacks Equity Research

                Aduro Biotech (ADRO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  BioMarin Presents Interim Data on BMN 250 from Phase I/II

                  by Zacks Equity Research

                  BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

                    Merck (MRK) Opts for Buying German Immuno-Oncology Biotech

                    by Zacks Equity Research

                    Merck (MRK) to acquire Germany-based Rigontec, a leader in retinoic acid-inducible gene I (RIG-I), a novel immuno-oncology treatment approach targeting therapeutics.

                      Mallinckrodt Down as District Court Invalidates Inomax Patents

                      by Zacks Equity Research

                      Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.

                        ProQR's QRX-421 Gets Orphan Drug Designation from FDA and EMA

                        by Zacks Equity Research

                        ProQR Therapeutics's (PRQR) pipeline candidate, QRX-421, has received orphan drug designation from the FDA and European Medicines Agency.

                          VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug

                          by Zacks Equity Research

                          VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.

                            Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study

                            by Zacks Equity Research

                            Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.

                              Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018

                              by Zacks Equity Research

                              Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018.

                                Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?

                                by Zacks Equity Research

                                Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.

                                  AMAG's Filing for Feraheme's Label Expansion Accepted by FDA

                                  by Zacks Equity Research

                                  AMAG Pharmaceuticals (AMAG) announced that the FDA accepted its submission for the label expansion of Feraheme (ferumoxytol) and has set an action date of Feb 2, 2018.

                                    Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval

                                    by Zacks Equity Research

                                    Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).

                                      Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia

                                      by Zacks Equity Research

                                      Teva Pharmaceutical (TEVA) announced that the FDA has approved the label expansion of Austedo to include tardive dyskinesia in adults. Shares are up since announcement.

                                        The Medicines Company's Infection Drug Vabomere Gets FDA Nod

                                        by Zacks Equity Research

                                        The Medicines Company's (MDCO) infection-resistant antibiotic Vabomere secures a fast FDA approval for urinary tract diseases. The drug is likely to hit the market in fourth-quarter 2017.

                                          BioMarin's Pegvaliase BLA Granted Priority Review by the FDA

                                          by Zacks Equity Research

                                          BioMarin Pharmaceutical (BMRN) announced that the FDA has accepted and granted priority review to the BLA for phenylketonuria candidate, Pegvaliase with a decision expected in February 2018.

                                            FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

                                            by Zacks Equity Research

                                            Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

                                              Advanced Accelerator Gets Action Date for Lutathera from FDA

                                              by Zacks Equity Research

                                              The FDA granted an action date for Lutathera after the company resubmitted the New Drug Application (NDA) for the candidate.

                                                The Medicines Co's Inclisiran Positive in Extension Study

                                                by Zacks Equity Research

                                                The Medicines Company (MDCO) and partner Alnylam publish new one-year safety and efficacy data from phase II extension study of Inclisiran for hypercholesterolemia.

                                                  Novo Nordisk's Tresiba Gets Canadian Nod

                                                  by Zacks Equity Research

                                                  Novo Nordisk's (NVO) Tresiba is approved by Health Canada for the once-daily treatment of adults with diabetes mellitus to improve glycemic control.